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BACKGROUND. The recent recommendation of the U.S. Preventive Services Task Force
against PSA-based screening for prostate cancer was based, in part, on the lack of demon-
strated diagnostic utility of serum PSA values in the low, but detectable range to successfully
predict prostate cancer. Though controversial, this recommendation reinforced the critical
need to develop, validate, and determine the utility of other serum and/or urine transcript
and protein markers as diagnostic markers for PCa. The studies described here were
intended to determine whether inflammatory cytokines might augment serum PSA as a diag-
nostic marker for prostate cancer.
METHODS. Multiplex ELISA assays were performed to quantify CCL1, CCL2, CCL5,
CCL8, CCL11, CCL17, CXCL1, CXCL5, CXCL8, CXCL10, CXCL12, and IL-6 protein levels in
the serum of 272 men demonstrating serum PSA values of <10 ng/ml and undergoing a 12
core diagnostic needle biopsy for detection of prostate cancer. Logistic regression was used to
identify the associations between specific chemokines and prostate cancer status adjusted for
prostate volume, and baseline PSA.
RESULTS. Serum levels for CCL1 (I-309) were significantly elevated among all men with
enlarged prostates (P < 0.04). Serum levels for CCL11 (Eotaxin-1) were significantly elevated
among men with prostate cancer regardless of prostate size (P < 0.01). The remaining 10
cytokines examined in this study did not exhibit significant correlations with either prostate
volume or cancer status.
CONCLUSIONS. Serum CCL11 values may provide a useful diagnostic tool to help distin-
guish between prostatic enlargement and prostate cancer among men demonstrating low,
but detectable, serum PSA values. Prostate 73: 573–581, 2013. # 2012 Wiley Periodicals, Inc.
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INTRODUCTION
Detection rates for prostate cancer in men demon-
strating total serum PSA values greater than 10 ng/
ml are typically 70% or higher when combined with
findings of abnormal digital rectal exam (DRE) or
with histological evidence based on greater than six
needle biopsy specimens [1,2]. These rates, however,
are much lower for men demonstrating low total se-
rum PSA (PSA) values of <10 ng/ml. For example,
malignant glands are detected on needle biopsy for
only 30% of men whose PSA values were between 4
and 10 ng/ml, and tumor detection rates fall to 21–
23% among men with detectable PSA values of
<4 ng/ml [3–6]. These studies suggest that low
(<10 ng/ml) PSA values are not diagnostic for PCa,
and that factors other than cancer may contribute to
the elevation in PSA in the serum, for example, pros-
tatitis or BPH. A recent study showed that a smaller
prostate volume is the strongest predictor of cancer
detection in men exhibiting PSA levels in the 2.0–
9.0 ng/ml range, suggesting that PSA is less useful
for the prediction of cancer in men with concurrent
BPH [7]. Several studies have shown that serum PSA
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values increase concomitantly with patient age in par-
allel with increased incidence of BPH [8–12].
Due, in part, to the lack of demonstrated screening
utility of serum PSA values in the low, but detectable
range (2.5–4.0 ng/ml), the U.S. Preventive Services
Task Force (USPSTF) recently recommended against
PSA-based screening for prostate cancer. This recom-
mendation is controversial and has been criticized for
not acknowledging the benefits of PSA screening, for
example, that PSA screening is associated with a sig-
nificant decline in prostate cancer-specific mortality
in the U.S. over the past two decades [13,14]. Even so,
the USPSTF recommendation does imply that low se-
rum PSA values alone do not reliably predict clinical-
ly significant prostate tumors. Therefore, there is a
critical need to develop, validate, and determine the
utility of other serum and/or urine transcript and
protein markers as diagnostic markers for PCa. Sever-
al markers identified and tested thus far, including
prostate-specific membrane antigen (PSMA), Hepsin,
a-methylacyl-coenzyme A racemase (AMACR), telo-
merase, the serine protease TMPRSS2, d-catenin, and
a prostate-specific non-coding RNA called PCA3 (for-
merly called DD3), when used alone or in combina-
tion with serum PSA, demonstrate variable utilities as
diagnostic or prognostic prostate cancer markers [15–
18]. Taken together, these studies show that addition-
al serum biomarkers would be very valuable to distin-
guish between prostatic diseases in men exhibiting
low but detectable serum PSA.
We have previously shown that aging prostate
stromal cells cultured in vitro secrete CXC-type che-
mokines, inflammatory proteins that act as potent
growth factors that promote the proliferation of both
non-transformed and transformed prostatic epithelial
cells [19–24]. These observations potentially link stro-
mally secreted inflammatory mediators with benign
and malignant proliferative diseases of the prostate.
We also reported preliminary studies suggesting that
CXCL5 and CXCL12 might have diagnostic utility to
distinguish PCa from BPH among men with low but
detectable serum PSA [25]. We have now expanded
these studies to test the efficacy of these and addition-
al inflammatory CXC-, CC-, and IL-type chemokines
and cytokines as serum biomarker for prostate cancer
diagnosis and prognosis in men exhibiting low but
detectable serum PSA values. The results of these
studies show that CCL11 (aka Eotaxin), a CC-type
chemokine not previously associated with prostatic
disease, is detected at significantly (P < 0.001) higher
levels in the serum of men with PCa than men with
BPH or no evidence of prostatic disease. Moreover,
serum CCL11 increases the diagnostic utility of serum
PSA to detect prostate cancer, even among men exhib-
iting low but detectable serum PSA. These data
suggest that serum CCL11 values may provide a use-
ful diagnostic tool to help distinguish between BPH
and PCa among men demonstrating low, but detect-
able, serum PSA values.
MATERIALSANDMETHODS
PatientPopulationandDemographics
The patient population was drawn from men re-
ferred to the University of Michigan Health System
(UMHS) with an indication for prostate biopsy, for ex-
ample, rising or elevated total prostate specific antigen
(PSA), abnormal digital rectal exam (DRE), high grade
prostatic intraepithelial neoplasia (HGPIN), or atypical
small acinar proliferation (ASAP) on prior biopsy, age,
positive family history of prostate cancer, and race/
ethnicity. The Prostate Cancer Prevention Trial Pros-
tate Cancer Risk Calculator (PCPTRC) was calculated
for each patient using this data [26]. As not all of these
men went on to have surgical treatment, only those
with radical prostatectomy at our center had addition-
al pathological annotation beyond the biopsy. Patients
presenting for a prostate biopsy were approached to
participate in an on-going prospective Prostate Biopsy
Clinical database/Tissue Bank study that enables sev-
eral studies with Institutional Review Board approval,
including the prostate biopsy referral database, the
Early Detection Research Network (EDRN), and the
study reported here. The final study population of 272
patients was selected for those exhibiting pre-biopsy
total serum PSA values of <10 ng/ml (determined
using the Abbott AxSYM polyclonal–monoclonal im-
munoassay [Abbott Diagnostics, Abbott Park, Ill]),
and that permitted examination of equivalent cases of
high volume disease within both the biopsy-negative
and -positive cases (Table I).
CollectionofClinicalData
Clinical and demographic data were collected from
the electronic medical record (UMHS Careweb) or
hard copy medical records for all subjects. This data
included patient age, date of biopsy, physician, serum
PSA levels, medical history, comorbid conditions,
medications, physical examination including DRE
findings, prior history of prostate biopsies, cost relat-
ed to the procedure, complications (AUA Symptom
Score/satisfaction with voiding situation), prostate
volume (PV) based on the transrectal ultrasound
(TRUS), and findings from the prostate biopsies. Also,
as patients were seen in follow-up, any changes in
disease status or additional diagnostic testing were
added to the database.
Prostate volume data was gathered during a stan-
dard TRUS examination performed using a 7.5 MHz
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biplanar endorectal probe. In addition to assessing
the echogenic pattern of the prostate gland, three
measurements were made to calculate total prostatic
volume. The anterior–posterior (AP) and transverse
(TR) diameters were measured at their respective
maximal dimensions, whereas the superior–inferior
(SI) diameter was measured as the maximal length
from the base to the apex of the prostate in the mid-
line sagittal plane. Total prostate volume was estimat-
ed by static images using the formula for a prolate
ellipsoid, volume ¼ p/6(TRxAPxSI).
CollectionofClinical Specimens
Serum samples were collected just prior to prostate
needle biopsy in order to obviate any potential surgi-
cal- or trauma-induced impact on circulating chemo-
kine or other protein levels in this patient group. As
standard procedure, all patients were advised to re-
frain from taking oral non-steroidal anti-inflammato-
ry drugs (NSAIDs) for 1 week prior to biopsy to
minimize bleeding. For all patients, blood was drawn
into 10 cm3 venous blood collection tubes (#366430,
Beckton, Dickinson, Franklin Lakes, NJ), which were
placed on ice and processed within 12 hr. The blood
was transferred into 15 ml tubes, centrifuged at
2,500 rpm for 10 min, and stored in 200 ml aliquots in
0.5 ml cryovials (Sarstedt, Newton, NC) at 808C.
The blood from the EDTA tube was diluted with an
equal volume of PBS and subjected to Ficoll Hypaque
density gradient centrifugation to separate the lym-
phocyte granulocyte layer (‘‘buffy coat’’) and plasma.
The plasma layer was carefully removed to a 15 ml
tube and centrifuged at 4,000 rpm for 10 min at 48C to
remove platelets and all cellular contaminants. The
platelet-free plasma was stored at 808C in 200 ml
aliquots in 0.5 ml cryovials (Sarstedt).
Prostate biopsies were typically performed trans-
rectally using a 12-core extended biopsy template
with traditional paramedian sextant biopsies plus ad-
ditional needle cores directed more laterally [27]. All
needle biopsies containing malignant glands were
quantitated as to percent of malignant tissue, and fur-
ther evaluation of perineural invasion or extrapro-
static extension was provided. All needle biopsies are
evaluated for the presence of HGPIN (high grade
prostatic intraepithelial neoplasia)/ASAP (atypical
small acinar proliferation), inflammation (acute and
chronic), hyperplasia, or other histopathologies.
When PCa was identified, each set of needle biopsies
TABLE I. PatientDemographic,Clinical, andHistopathologicalData
Category Sub-category
All
patients
No
disease BPH PCa-BPH PCa þ BPH P-value Method
Total number 272 68 71 67 66
Median prostate
volume (range)
40.7
(16.2–279.0)
33
(18–40)
60.7
(40.2–132.0)
32.8
(16.2–40.0)
57.5
(40.7–279.0)
<0.0001 Kruskal–Wallis
Mean pre-biopsy
PSA, pg/ml (SE)
5.0 (0.1) 3.9 (0.3) 5.4 (0.3) 5.2 (0.3) 5.5 (0.2) 0.0001 One-way
ANOVA
Ethnicity Caucasian (%) 229 54 (23.6) 60 (26.2) 57 (24.9) 58 (25.3) 0.1 Chi-squared
African
American (%)
19 4 (21.1) 3 (15.8) 6 (31.6) 6 (31.6)
Asian (%) 18 9 (50.0) 6 (33.3) 2 (11.1) 1 (5.6)
Other/ND 6
Median Gleason
sum (range)
7 (6–9) ND ND 7 (6–9) 7 (6–9) 0.11 Wilcoxon rank
sum test
Mean age at
surgery (SE)
61.4 (0.5) 58.4 (1.1) 61.2 (0.9) 60.9 (1.0) 65.0 (0.9) 0.0002 One-way
ANOVA
Family history Yes (%) 79 16 (20.3) 18 (22.8) 25 (31.7) 20 (25.3) 0.27 Chi-squared
No (%) 191 52 (27.2) 52 (27.2) 41 (21.5) 46 (24.1)
ND 2
DRE results Normal (%) 59 25 (42.4) 7 (11.9) 21 (35.6) 6 (10.2) <0.0001 Fisher’s
exact testEnlarged,
benign (%)
152 25 (16.5) 51 (33.6) 29 (19.1) 47 (31.0)
Enlarged/
asymmetric (%)
10 0 (0) 4 (40.0) 3 (30.0) 3 (30.0)
Abnormal, cancer
suspicious (%)
51 18 (35.3) 9 (17.7) 14 (27.5) 10 (19.6)
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was given an overall Gleason grade based on evalua-
tion of the entire tumor.
DefinitionsofProstaticDiseaseStatus
andStudyGroups
Disease status was carefully defined in the study
group, as delineated below and detailed in Table I.
No disease. Criteria: No finding of cancer on prostate
biopsy. Prostate volume <40 g on TRUS. Prostate bi-
opsy specimens evaluated as normal benign. PSA val-
ues <10 ng/ml. This comprised 68/272 (25%) of the
total patient population examined in this study.
BPH. Criteria: Evidence for enlarged prostate, defined
as 40 g, roughly equivalent to measures described as
high-volume and consistent with BPH in the literature
[7]. Men with enlarged prostates that were biopsy-
negative for prostate cancer. These patients comprised
71/272 (26%) of the total patient population examined
in this study. Although the American Urological Asso-
ciation Symptom Index (AUASI) was recorded for all
patients, it was not used to define BPH.
BPH concurrent with PCa. Criteria: Men with en-
larged prostates as defined above and biopsy-positive
for prostate cancer. Cancer was assessed from a histo-
logical diagnosis of malignant glands in one or more
diagnostic needle biopsies. Five board-certified path-
ologists were involved in the histologic diagnoses
of the prostate biopsies. These patients comprised
66/272 (24%) of the total patient population examined
in this study.
PCa in the absence of BPH. Criteria: Men with pros-
tates <40 g and biopsy-positive for prostate cancer.
These patients comprised 67/272 (25%) of the total
patient population examined in this study.
MultiplexELISAAssays
Multiplex ELISA assays were performed by
QUANSYS Biosciences (Logan, UT). The arrays were
modified from the QUANSYS human cytokine array
to include capture antibodies for CCL1 (I-309), CCL2
(MCP-1), CCL5 (RANTES), CCL8 (MCP-2), CCL11
(Eotaxin), CCL17 (TARC), CXCL1 (GRO-a), CXCL5
(ENA-78), CXCL8 (IL-8), CXCL10 (IP-10), CXCL12
(SDF-1), and IL-6 spotted in a 3  4 grid into the bot-
tom of each well of a 96-well-plate. Each spotted well
received 30 ml serum, the plate incubated for 1 hr,
wells washed, and 30 ml of a pooled detection anti-
body cocktail was added. The plate was incubated for
1 hr, washed, and streptavidin bound to horse radish
peroxidase (HRP) was added. Chemiluminscence was
visualized and imaged using a Q-View Imager and
signals quantitated against standard curves generated
from known standards included on the plates using
Q-View Software. Each assay was performed in tripli-
cate and the resulting data was averaged. For the
assays utilized on the modified human cytokine array
using undiluted samples, the coefficient of variation
(CV) between assays within a triplicate set varied for
each assay, with assays for CCL11, CCL8, and CXCL5
demonstrating the lowest (<5%) CVs, followed by
CXCL8, CXCL10, CCL2, CCL5, and CCL17 (5–10%),
CXCL1 and CCL1 (10–15%), and IL-6 (20%; Table II).
StatisticalAnalysis
The bivariate relationship of circulating cyto-
kine/chemokine levels and disease status was tested
in this patient population using the non-parametric
Wilcoxon rank-sum test, as we have done previous-
ly with a similar but smaller dataset [25]. Separate
tests were performed for each definition of disease
in pairwise fashion. Multivariable analyses receiver
operator curve (ROC) analyses were pursued to
examine sensitivity and specificity for individual
chemokines as predictors of disease and to calculate
the area under the curve (AUC) and confidence
intervals (CIs). The logistic regression was used to
identify the statistic association between specific
chemokines and prostate disease status adjusted
for prostate volume, and baseline PSA. Backward
model building procedure were used to determine
the most parsimonious models for various prostate
TABLE II. PercentCoefficientofVariation(%CV) for IndividualAssays
% CV
CCL11
(Eotaxin-1)a
CXCL1
(GRO-a)
CCL1
(I-309)
CXCL8
(IL-8)
CXCL10
(IP-10)
CCL2
(MCP-1)
CCL8
(MCP-2)
CCL5
(RANTES)
CCL17
(TARC) IL-6
CXCL5
(ENA-78)
5% 5.0 4.9 4.6
>5–10% 7.7 5.6 5.3 6.1 8.0
>10–15% 14.5 13.7
>15–20% 20
aFormer nomenclature is shown in parentheses.
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disease statuses. All tests were performed using
SAS v 9.2 at the 5% significance level.
RESULTS
As shown in Table I, the four patient groups in-
cluded in this study—men with no prostatic disease,
with BPH, with PCa in the absence of BPH, or with
PCa concurrent with BPH—differed significantly for
prostate size, pre-biopsy PSA, age at surgery, DRE
results, and presence or absence of malignant glands
in the prostate. Men with concurrent PCa and BPH
were significantly older than men with no disease,
BPH alone, or PCa without BPH (Table I). Men with
no disease demonstrated significantly lower pre-biop-
sy serum PSA values than men in the other three pa-
tient groups (Table I).
The levels of 12 proteins—CCL1 (I-309), CCL2
(MCP-1), CCL5 (RANTES), CCL8 (MCP-2), CCL11
(Eotaxin-1), CCL17 (TARC), CXCL1 (GRO-a), CXCL5
(ENA-78), CXCL8 (IL-8), CXCL10 (IP-10), CXCL12
(SDF-1), and IL-6 were measured by multiplex ELISA
in serum from 272 patients who presented with low
but detectable serum PSA levels of <10 ng/ml. All of
these proteins were robustly, though differentially,
detectable in the serum of these patients (Table III)
with the exception of CXCL12. The assays for CXCL5
and CXCL12 were custom-designed by Quansys Bio-
sciences specifically for this study. Intra-assay preci-
sion tests performed as part of the development of
these assays showed that percent recovery (detection)
of known levels of recombinant CXCL5 was 93%, well
within the desired range of 80–120% defined by
Quansys Biosciences. However, the percent recovery
of known levels of recombinant CXCL12 was only
63%, much lower than desired. Of the 272 patient
serum samples tested, CXCL12 was detected in only
12 samples. The only known receptor for CXCL12,
CXCR4, is present on platelets in serum, which can
bind CXCL12 with high affinity, making CXCL12 un-
available for binding to the capture antibody in an
ELISA assay [28–31]. Thus, serum levels of CXCL12
could not be reliably measured in this study.
The protein with the highest measured serum level
in this study was RANTES (CCL5), which averaged
>22,000 pg/ml across all four patient groups
(Table III). Conversely, the protein with the lowest
measured serum level was IL-6, which averaged only
3.63–6.65 pg/ml across all four patient groups
(Table III). Neither these nor CCL2, CCL8, CCL17,
CXCL1, CXCL5, CXCL8, or CXCL10 demonstrated
significantly different serum levels across the four pa-
tient groups included in this study (Table III).
Two serum proteins, CCL1 (I-309) and CCL11
(Eotaxin-1), were differentially represented in the se-
rum of the patient groups tested in this study. Serum
levels for CCL1 differed significantly between the four
patient groups (P < 0.04). Logistic regression showed
that serum CCL1 levels were significantly elevated
(P ¼ 0.017) among all men with enlarged prostates,
defined as TRUS PV 40 g (Table III). Serum levels
for CCL11 also differed significantly between the four
patient groups (CCL11) (P < 0.01) and were specifical-
ly elevated among men with prostate cancer regard-
less of prostate size. Moreover, serum CCL11 levels
for men biopsy-negative for prostate cancer (no dis-
ease or BPH alone) averaged 101 pg/ml, whereas
those for men biopsy-positive for prostate cancer
(PCa þ BPH and PCa-BPH) were significantly
(P < 0.001) higher and averaged 128 pg/ml
(Table IV). Thus, CCL11 successfully identified pros-
tate tumors in men independent of prostate volume.
TABLE III. SerumChemokineandCytokineLevels
Serum protein
No disease (N ¼ 68) BPH (N ¼ 71) PCa-BPH (N ¼ 67) PCa þ BPH (N ¼ 66)
P-valueMean SEa Mean SE Mean SE Mean SE
CCL1 6.37 0.82 8.38 0.79 7.33 0.85 9.57 0.87 0.04
CCL2 198.29 9.95 209.63 9.7 216.95 9.97 217.02 10.03 0.50
CCL5 22565.00 1706.48 22122.94 1657.89 24684.02 1709.85 25972.93 1726.05 0.34
CCL8 27.26 1.51 26.01 1.47 27.92 1.51 24.73 1.53 0.46
CCL11 99.19 8.21 104.2 7.95 123.24 8.23 133.69 8.24 0.01
CCL17 191.33 15.59 189.14 15.09 198.01 15.63 200.6 15.71 0.95
CXCL1 16.98 3.09 13.98 3.5 9.68 3.06 16.95 3.36 0.33
CXCL5 4015.22 528.29 3618.64 605.58 4546.48 576.63 3633.13 579.97 0.64
CXCL8 6.66 0.48 7.37 0.46 6.97 0.48 7.61 0.48 0.51
CXCL10 76.77 8.94 65.16 8.65 62.44 8.96 70.32 9.11 0.68
IL-6 5.12 1.24 3.78 1.15 3.63 1.28 6.65 1.27 0.28
All values are pg/ml.
aSE, standard error of the mean.
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We next compared the ability of serum CCL11 to
serum PSA to predict prostate tumors. The AUC cal-
culated in this patient set using logistic regression
and ROC analyses was 0.57 (CI 0.51–0.66) for PSA
and 0.56 (CI 0.48–0.64) for CCL11. When combined,
CCL11 þ PSA increased the AUC to 0.62 (CI 0.54–
0.69), indicating that CCL11 þ PSA serum levels bet-
ter predicted the presence of prostate cancer than
either PSA or CCL11 alone (Fig. 1). However, this
difference between the predictive values of CCL11
and PSA (P ¼ 0.65) and between CCL11 þ PSA com-
pared to that of PSA alone (P ¼ 0.18) did not reach
statistical significance (P ¼ 0.18). Similarly, the ability
of CCL11 to predict prostate cancer was compared to
that of The Prostate Cancer Prevention Trial Prostate
Cancer Risk Calculator (PCPTRC) [26]. The AUC cal-
culated in this patient set using logistic regression
and ROC analyses was 0.60 (CI 0.53–0.68) for the
PCPTRC. When combined, CCL11 þ PCPTRC in-
creased the AUC to 0.64 (CI 0.56–0.71), indicating that
CCL11 serum levels combined with PCPTRC risk
analysis better predicted the presence of prostate can-
cer than either CCL11 or PCPTRC alone (Fig. 1). How-
ever, this difference between the predictive values
of CCL11 and PCPTRC (P ¼ 0.39) and between
CCL11 þ PCPTRC compared to that of PCPTRC
alone (P ¼ 0.19) did not reach statistical significance.
Thus, although CCL11 successfully identified prostate
tumors in men independent of prostate volume,
the predictive value of CCL11 was not significantly
different from that of either PSA or PCPTRC.
DISCUSSION
The studies described here were intended to deter-
mine whether cytokine and/or chemokine serum
proteins could be identified that might augment or
replace serum PSA as a diagnostic marker for prostate
cancer.
Although 12 markers were initially investigated
as potential prostate cancer biomarkers, only two—
CCL1 and CCL11—demonstrated utility in this
regard. One of them, CCL1, actually demonstrated
elevated levels in association with BPH rather than PCa.
CCL1 is a small (15–18 kdal) secreted glycoprotein
and is the sole ligand for the G-protein coupled recep-
tor, CCR8 [32]. An earlier study had described elevat-
ed levels of CCL1 in seminal plasmas from patients
TABLE IV. SerumChemokineandCytokineLevelsinPatientsHarboringNon-cancerousorCancerousProstates
No cancer Cancer P-value
CCL11 101.36  5.68 128.16  5.80 0.001
CCL1 7.33  0.58 8.44  0.61 0.190
CCL2 204.08  6.93 216.99  7.05 0.190
CCL5 22339.28  1185.27 25323.63  1210.77 0.080
CCL8 26.62  1.06 26.35  1.08 0.860
CCL17 190.21  10.80 199.29  11.04 0.560
CXCL1 15.37  2.34 13.17  2.30 0.500
CXCL5 3845.26  397.93 4081.79  408.84 0.680
CXCL8 7.03  0.33 7.29  0.34 0.580
CXCL10 70.84  6.21 66.32  6.38 0.610
IL-6 4.44  0.85 5.13  0.90 0.580
All values are pg/ml. Data shown is mean  SD.
Fig. 1. SerumCCL11levels increase thediagnosticutilityof serum
PSAandPCPTRCrisk analysis topredictprostate cancer.Receiver-
operator curves demonstrating the ability of serum PSA,PCPTRC
(PCTP), and serumCCL11, alone or incombination, topredictpros-
tate cancer on patients with serum PSA <10 ng/ml (N ¼ 272).
The area under the curve (AUC) for each measure is indicated in
parentheses.
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with BPH [33]. Although high levels of CCL1 protein
have now been identified in both the serum and semi-
nal fluid of men with enlarged prostates, the cellular
source for CCL1 expression is likely activated T-cells
[34] in the prostate tissue microenvironment. The
CCR8 receptor is expressed on a variety of cell types
including monocytes and endothelial cells and is
selectively up-regulated upon activation of T-helper-2
(Th2) cells [35]. Inflammatory infiltrates are very com-
monly observed in BPH specimens and comprise 70%
T lymphocytes, 15% B cells, and 15% macrophages as
well as mast cells [36–38]. The T lymphocyte popula-
tion in particular expands enormously in BPH/LUTS,
increasing from a mean of 7 cells/mm2 in the normal
prostate to a mean of 195 cells/mm2 in fully devel-
oped BPH [38]. Therefore, it is not surprising that a
chemokine largely secreted by activated T-cells may
be found at significantly elevated levels in the serum
of men with enlarged prostates. Other studies have
demonstrated that T-lymphocytes promoted the pro-
liferation of both transformed and non-transformed
prostate epithelial cell lines in vitro [39], suggesting
that high serum levels of CCL1 may signify the pres-
ence of large T-lymphocyte populations in the pros-
tate that, in turn, promote prostate tissue proliferation
and prostatic enlargement.
The second serum protein biomarker identified in
this study, CCL11 (Eotaxin-1), is a potent chemotactic
factor for eosinophils [40]. CCL11 is a ligand for the
G-protein coupled receptor, CCR3, which is
expressed on eosinophils, basophils, and Th2 helper
T-cells [41–43]. Very little is known regarding poten-
tial role(s) for CCL11 in prostate pathology. A recent
study reported up-regulation of CCL11 transcript and
those of many other CXC- and CC-type chemokines
in a mouse model of experimental autoimmune pros-
tatitis [44]. Another study reported up-regulation of
CCL11 in the prostates of male Wistar rats chronically
exposed to estradiol [45]. Although there are no
reports examining serum CCL11 levels in men with
benign or malignant prostatic disease, several studies
report that elevated serum CCL11 levels are diagnos-
tic or prognostic for other human cancers. For exam-
ple, a recent study showed that elevated serum
CCL11 and osteopontin levels were significantly
(P ¼ 0.016 and 0.021, respectively) associated with
disease progression in patients with head and neck
small cell carcinomas (HNSCCs) receiving induction
therapy on a Phase II trial of carboplatin, paclitaxel,
and cetuximab [46]. Another study demonstrated that
CCR3 expression correlated with high grade renal cell
carcinomas (RCCs) [47]. Moreover, this study showed
that A-498 renal cancer cells demonstrated a robust
proliferative response to treatment with CCL11 in
vitro [47]. In a mouse model of skeletal breast cancer
metastasis, vascular endothelial growth factor (VEGF)
and CCL11 levels were significantly higher in the fe-
murs of cancer cell-inoculated compared to sham-in-
oculated mice [48]. This study speculated that the
pro-angiogenic functions of VEGF and CCL11 may
enable metastatic cancer cells to colonize and thrive in
the bone environment [48]. A proteomics approach
recently identified high plasma levels of CCL11 as
predictive for high risk neuroblastoma, and included
CCL11 levels within a 7-protein classifier set of plas-
ma proteins potentially useful for the detection of re-
lapse prior to the development of clinically evident
disease [49]. Taken together, these studies are consis-
tent with the use of CCL11 plasma or serum levels as
diagnostic or prognostic cancer markers.
Lastly, the studies reported here also showed that
the combined use of serum CCL11 levels with serum
PSA or PCPTRC risk analysis increases the diagnostic
utility of all of these measures to detect prostate can-
cer, even among men exhibiting low but detectable
serum PSA. Recent studies have demonstrated the
utility of ‘adding’ PCA3 and TMPRSS2/ERG urine
transcript levels to serum PSA levels or PCPTRC risk
analysis to improve prostate cancer diagnosis [50].
Clearly, there is a need to continue to identify and
validate serum, plasma, and urine biomarkers that
can be used in combination to identify men at high
risk for harboring clinically significant prostate
tumors. In this way, initial screening tools can be de-
veloped and tested that enable clinicians to make
sound recommendations for the use of secondary di-
agnostic tools, such as ultrasound and needle biopsy,
to accurately detect clinically significant prostate
tumors.
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